Screener
Rhythm Pharmaceuticals, Inc. RYTM Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Liabilities, Convertible Preferred Stock and Stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $12,299 | $13,947 |
| Accrued expenses and other current liabilities | 80,045 | 83,855 |
| Lease liability | 676 | 650 |
| Deferred revenue | 48 | 194 |
| Deferred royalty obligation, current | 10,130 | 7,296 |
| Total current liabilities | 103,198 | 105,942 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s accrued expenses?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported accrued expenses of $80.05M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s accrued expenses changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s accrued expenses increased by 106.4% year-over-year, from $38.78M to $80.05M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Rhythm Pharmaceuticals, Inc.'s accrued expenses has grown at a 46.2% compound annual growth rate (CAGR), from $12.56M to $83.86M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude